Given the high risk for T1D patients to develop cardiovascular diseases, and the established role of impaired insulin and autophagy pathways in these diseases, we proposed to analyze the impact of an ACE inhibitor, Cap on the metabolic impairments in a T1D mouse model. The gene discussed is ACE; the disease is type 1 diabetes mellitus.